Current CSO of Biotheus. Ph.D., University of Oxford, UK, post-doctorate at the Shanghai Pasteur Institute of the Chinese Academy of Sciences. Served as Associate Professor at the Shanghai Pasteur Institute of the Chinese Academy of Sciences and lead three National Natural Science Foundation projects as SME. As the core scientist of the joint research project between Chinese Academy of Sciences and international pharmaceutical companies, he has published nearly 35 papers in international academic journals. Andy was once the Director New Drug Research of Innovent Biologics, responsible for the functional biology research of new tumor immunotherapy antibody drugs. During this period, as the deputy project leader, he participated and led the whole process from drug discovery, cell line development to clinical trial application of the anti-tumor antibody drug PD-1 antibody-Sintilimab. Andy also led the discovery and development of multiple therapeutic antibodies such as OX40, CD47 and LAG-3.